Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis

@article{Goldvaser2018InfluenceOC,
  title={Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis},
  author={Hadar Goldvaser and Habeeb Majeed and Domen Ribnikar and Bo{\vs}tjan {\vS}eruga and Alberto Oca{\~n}a and David W. Cescon and Eitan Amir},
  journal={Breast Cancer Research and Treatment},
  year={2018},
  volume={169},
  pages={413-425}
}
PurposeResults from clinical trials of adjuvant dose-dense chemotherapy in patients with breast cancer are inconsistent.MethodsA systematic search of MEDLINE identified studies comparing the efficacy of dose-dense adjuvant chemotherapy to a standard treatment. The primary analysis included studies that used identical regimens in the experimental and control groups, but varied only dose density. A secondary analysis included studies that used either different drugs or doses in the experimental… 
Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer.
TLDR
Chemotherapy TCD <85% for adjuvant FEC-D affects breast cancer survival, and late reductions (D only) were not shown to adversely affect DFS or OS Conversely, early reductions (FEC±D) negatively affected patient outcomes.
Adjuvant Systemic Treatment in Hormone Receptor Positive, HER2 Negative Breast Cancer
  • F. Sen
  • Medicine, Biology
    Breast Cancer and Surgery
  • 2018
TLDR
The introduction of adjuvant systemic therapy led to a significant improvement in postsurgical survival and a reduction in disease relapse in postmenopausal women with early stage breast cancer.
Chapter 7 Adjuvant Systemic Treatment in Hormone Receptor Positive , HER 2 Negative Breast Cancer
TLDR
The introduction of adjuvant systemic therapy led to a significant improvement in postsurgical survival and a reduction in disease relapse in postmenopausal women with early stage breast cancer.
Should perioperative chemotherapy in triple negative breast cancer routinely comprise platinum salts? A vote for no
TLDR
Most patients respond well to standard chemotherapy and there is no need to include platinum derivatives in perioperative therapies, but one should remember that platinum salts use not only increases the percentage of pCRs, but also results in an increased therapeutic toxicity.
Positive sentinel node in luminal A-like breast cancer patients - implications for adjuvant chemotherapy?
TLDR
The SN ratio may aid in identifying many of patients with SN positive luminal A-like tumors who are no longer recommended an axillary lymph node dissection (ALND) risk undertreatment, especially if they have ≥4 lymph node metastases (LNMs).
A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles
TLDR
This comprehensive Canadian guideline on NABC includes the use of neoadjuvant therapy for early stage triple negative and HER2 positive breast cancer, with subsequent adjuvant treatments for patients with residual disease.
Predictors of Lymph Node Metastasis in Primary Breast Cancer - Risk Models for Tailored Axillary Management
TLDR
The ability to estimate axillary nodal burden using preoperatively obtainable predictors and highlight nonlinear associations between clinicopathological variables and nodal metastasis are demonstrated.
...
...

References

SHOWING 1-10 OF 34 REFERENCES
Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials
TLDR
DD-CT leads to better overall survival and disease-free survival, particularly in women with ER− early BC, and should be the standard care offered to high-risk ER− BC patients.
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
TLDR
The results support the long-term safety of FEC14 chemotherapy as an adjuvant treatment of breast cancer and find no evidence that the effect of the treatment type was associated with any of the potential prognostic factors.
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
TLDR
Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival.
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
TLDR
The addition of a taxane to an anthracycline-based regimen improves the DFS and OS of high-risk EBC patients and was independent of ER expression, degree of nodal involvement, type of taxane, age/menopausal status of patient, and administration schedule.
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
  • M. Untch, V. Möbus, G. Konecny
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
IDD was less well tolerated compared to standard treatment, but improved clinical outcomes in patients with noninflammatory high-risk primary BC, and support the efficacy and short-term safety of IDD as preoperative chemotherapy.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
  • M. Citron, D. Berry, L. Norton
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Dose density improves clinical outcomes significantly, despite the lower than expected number of events at this time, and Sequential chemotherapy is as effective as concurrent chemotherapy.
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
  • V. Moebus, C. Jackisch, M. Untch
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
IDD-ETC was less well tolerated compared with conventional chemotherapy but significantly improved event-free and overall survivals in patients with high-risk primary breast cancer who had four or more positive axillary lymph nodes.
...
...